Literature DB >> 24866401

Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers.

Marka van Blitterswijk1, Bianca Mullen1, Michael G Heckman2, Matthew C Baker1, Mariely DeJesus-Hernandez1, Patricia H Brown1, Melissa E Murray1, Ging-Yuek R Hsiung3, Heather Stewart3, Anna M Karydas4, Elizabeth Finger5, Andrew Kertesz5, Eileen H Bigio6, Sandra Weintraub6, Marsel Mesulam6, Kimmo J Hatanpaa7, Charles L White7, Manuela Neumann8, Michael J Strong9, Thomas G Beach10, Zbigniew K Wszolek11, Carol Lippa12, Richard Caselli13, Leonard Petrucelli1, Keith A Josephs14, Joseph E Parisi14, David S Knopman14, Ronald C Petersen14, Ian R Mackenzie15, William W Seeley4, Lea T Grinberg4, Bruce L Miller4, Kevin B Boylan11, Neill R Graff-Radford11, Bradley F Boeve14, Dennis W Dickson1, Rosa Rademakers16.   

Abstract

Repeat expansions in chromosome 9 open reading frame 72 (C9ORF72) are an important cause of both motor neuron disease (MND) and frontotemporal dementia (FTD). Currently, little is known about factors that could account for the phenotypic heterogeneity detected in C9ORF72 expansion carriers. In this study, we investigated 4 genes that could represent genetic modifiers: ataxin-2 (ATXN2), non-imprinted in Prader-Willi/Angelman syndrome 1 (NIPA1), survival motor neuron 1 (SMN1), and survival motor neuron 2 (SMN2). Assessment of these genes, in a unique cohort of 331 C9ORF72 expansion carriers and 376 control subjects, revealed that intermediate repeat lengths in ATXN2 possibly act as disease modifier in C9ORF72 expansion carriers; no evidence was provided for a potential role of NIPA1, SMN1, or SMN2. The effects of intermediate ATXN2 repeats were most profound in probands with MND or FTD/MND (2.1% vs. 0% in control subjects, p = 0.013), whereas the frequency in probands with FTD was identical to control subjects. Though intermediate ATXN2 repeats were already known to be associated with MND risk, previous reports did not focus on individuals with clear pathogenic mutations, such as repeat expansions in C9ORF72. Based on our present findings, we postulate that intermediate ATXN2 repeat lengths may render C9ORF72 expansion carriers more susceptible to the development of MND; further studies are needed, however, to validate our findings.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATXN2; Amyotrophic lateral sclerosis; Ataxin-2; C9ORF72; Disease modifier; Frontotemporal dementia; Motor neuron disease

Mesh:

Substances:

Year:  2014        PMID: 24866401      PMCID: PMC4105839          DOI: 10.1016/j.neurobiolaging.2014.04.016

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  30 in total

1.  Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS.

Authors:  J H Veldink; L H van den Berg; J M Cobben; R P Stulp; J M De Jong; O J Vogels; F Baas; J H Wokke; H Scheffer
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

2.  Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease.

Authors:  Serena Lattante; Amelia Conte; Marcella Zollino; Marco Luigetti; Alessandra Del Grande; Giuseppe Marangi; Angela Romano; Alessandro Marcaccio; Emiliana Meleo; Giulia Bisogni; Paolo Maria Rossini; Mario Sabatelli
Journal:  Neurology       Date:  2012-06-20       Impact factor: 9.910

3.  ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion.

Authors:  G Sorarù; M Clementi; M Forzan; V Orsetti; C D'Ascenzo; G Querin; A Palmieri; M Ermani; C Angelini; E Pegoraro
Journal:  Neurology       Date:  2011-06-07       Impact factor: 9.910

4.  NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis.

Authors:  Hylke M Blauw; Wouter van Rheenen; Max Koppers; Philip Van Damme; Stefan Waibel; Robin Lemmens; Paul W J van Vught; Thomas Meyer; Claudia Schulte; Thomas Gasser; Edwin Cuppen; R Jeroen Pasterkamp; Wim Robberecht; Albert C Ludolph; Jan H Veldink; Leonard H van den Berg
Journal:  Hum Mol Genet       Date:  2012-02-28       Impact factor: 6.150

5.  SMN1 gene, but not SMN2, is a risk factor for sporadic ALS.

Authors:  P Corcia; W Camu; J-M Halimi; P Vourc'h; C Antar; S Vedrine; B Giraudeau; B de Toffol; C R Andres
Journal:  Neurology       Date:  2006-08-23       Impact factor: 9.910

6.  SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS.

Authors:  J H Veldink; S Kalmijn; A H Van der Hout; H H Lemmink; G J Groeneveld; C Lummen; H Scheffer; J H J Wokke; L H Van den Berg
Journal:  Neurology       Date:  2005-08-10       Impact factor: 9.910

7.  Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.

Authors:  Teresa Lee; Yun R Li; Caroline Ingre; Markus Weber; Torsten Grehl; Ole Gredal; Mamede de Carvalho; Thomas Meyer; Ole-Björn Tysnes; Georg Auburger; Suzana Gispert; Nancy M Bonini; Peter M Andersen; Aaron D Gitler
Journal:  Hum Mol Genet       Date:  2011-02-03       Impact factor: 6.150

8.  Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis.

Authors:  Philippe Corcia; Véronique Mayeux-Portas; Jawad Khoris; Bertrand de Toffol; Alain Autret; Jean-Pierre Müh; William Camu; Christian Andres
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

9.  Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.

Authors:  Andrew C Elden; Hyung-Jun Kim; Michael P Hart; Alice S Chen-Plotkin; Brian S Johnson; Xiaodong Fang; Maria Armakola; Felix Geser; Robert Greene; Min Min Lu; Arun Padmanabhan; Dana Clay-Falcone; Leo McCluskey; Lauren Elman; Denise Juhr; Peter J Gruber; Udo Rüb; Georg Auburger; John Q Trojanowski; Virginia M-Y Lee; Vivianna M Van Deerlin; Nancy M Bonini; Aaron D Gitler
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

10.  ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population.

Authors:  Suna Lahut; Özgür Ömür; Özgün Uyan; Zeynep Sena Ağım; Aslihan Özoğuz; Yeşim Parman; Feza Deymeer; Piraye Oflazer; Filiz Koç; Hilmi Özçelik; Georg Auburger; A Nazlı Başak
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more
  38 in total

Review 1.  Emerging role of RNA•DNA hybrids in C9orf72-linked neurodegeneration.

Authors:  Jiou Wang; Aaron R Haeusler; Eric A J Simko
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  The Genetics of C9orf72 Expansions.

Authors:  Ilse Gijselinck; Marc Cruts; Christine Van Broeckhoven
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 3.  Tandem repeats mediating genetic plasticity in health and disease.

Authors:  Anthony J Hannan
Journal:  Nat Rev Genet       Date:  2018-02-05       Impact factor: 53.242

4.  Analysis of the GCG repeat length in NIPA1 gene in C9orf72-mediated ALS in a large Italian ALS cohort.

Authors:  Lucia Corrado; Maura Brunetti; Alice Di Pierro; Marco Barberis; Roberta Croce; Enrica Bersano; Fabiola De Marchi; Miriam Zuccalà; Nadia Barizzone; Andrea Calvo; Cristina Moglia; Letizia Mazzini; Adriano Chiò; Sandra D'Alfonso
Journal:  Neurol Sci       Date:  2019-07-09       Impact factor: 3.307

Review 5.  Frontotemporal dementia: a bridge between dementia and neuromuscular disease.

Authors:  Adeline S L Ng; Rosa Rademakers; Bruce L Miller
Journal:  Ann N Y Acad Sci       Date:  2014-12-30       Impact factor: 5.691

6.  Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis.

Authors:  Stella A Glasmacher; Charis Wong; Iona E Pearson; Suvankar Pal
Journal:  JAMA Neurol       Date:  2020-03-01       Impact factor: 18.302

7.  ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry.

Authors:  Giuseppe Borghero; Maura Pugliatti; Francesco Marrosu; Maria Giovanna Marrosu; Maria Rita Murru; Gianluca Floris; Antonino Cannas; Leslie D Parish; Tea B Cau; Daniela Loi; Anna Ticca; Sebastiano Traccis; Umberto Manera; Antonio Canosa; Cristina Moglia; Andrea Calvo; Marco Barberis; Maura Brunetti; Alan E Renton; Mike A Nalls; Bryan J Traynor; Gabriella Restagno; Adriano Chiò
Journal:  Neurobiol Aging       Date:  2015-06-25       Impact factor: 4.673

Review 8.  R Loops and Links to Human Disease.

Authors:  Patricia Richard; James L Manley
Journal:  J Mol Biol       Date:  2016-09-04       Impact factor: 5.469

9.  ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion.

Authors:  Adriano Chiò; Gabriele Mora; Mario Sabatelli; Claudia Caponnetto; Christian Lunetta; Bryan J Traynor; Janel O Johnson; Mike A Nalls; Andrea Calvo; Cristina Moglia; Giuseppe Borghero; Francesca Trojsi; Vincenzo La Bella; Paolo Volanti; Isabella Simone; Fabrizio Salvi; Francesco O Logullo; Nilo Riva; Paola Carrera; Fabio Giannini; Jessica Mandrioli; Raffaella Tanel; Margherita Capasso; Lucio Tremolizzo; Stefania Battistini; Maria Rita Murru; Paola Origone; Marcella Zollino; Silvana Penco; Letizia Mazzini; Sandra D'Alfonso; Gabriella Restagno; Maura Brunetti; Marco Barberis; Francesca L Conforti
Journal:  Neurobiol Aging       Date:  2015-12-08       Impact factor: 4.673

Review 10.  New Roles for Canonical Transcription Factors in Repeat Expansion Diseases.

Authors:  Lindsey D Goodman; Nancy M Bonini
Journal:  Trends Genet       Date:  2019-12-11       Impact factor: 11.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.